Evidence map›Paper›PMID 41799067›Full record

ArticleACS omega2026

Computational Studies toward the Identification of CB2R-M1R Dual Modulators.

Israa H Isawi, Rufaida Al-Zoubi, Rima Hajjo, Rayan M Obeidat, Islam H AlKhawaldeh, Omar M Al Kilani, Mahmoud J Alhaj Hasan, Paula Morales

Abstract read
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Israa H IsawiDepartment of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan.ORCID https://orcid.org/0000-0002-4342-5370
Rufaida Al-ZoubiDepartment of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan.
Rima HajjoDepartment of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman 11733, Jordan.
Rayan M ObeidatDepartment of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan.
Islam H AlKhawaldehDepartment of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan.
Omar M Al KilaniDepartment of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan.
Mahmoud J Alhaj HasanDepartment of Computer Science, Faculty of Computer and Information Technology, Jordan University of Science and Technology, Irbid 22110, Jordan.
Paula MoralesInstituto de Química Médica, Consejo Superior de Investigaciones Científicas (IQM-CSIC), Madrid 28006, Spain.ORCID https://orcid.org/0000-0002-6209-8600

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The complex and multifactorial nature of different neurodegenerative disorders hampers the capacity to identify effective treatments. Therefore, instead of relying solely on monotherapies or combination therapies, which typically come with dosing complications and limited synergy, multitarget-directed ligand strategies have emerged as one of the most dynamic and promising approaches to improve outcomes for such diseases. This study sought to identify dual modulators that specifically target cannabinoid receptor type 2 (CB2R) and muscarinic acetylcholine receptor subtype 1 (M1R), two receptors involved in various physiological and neurological processes and frequently implicated in disorders like Alzheimer's, Parkinson's, and chronic pain. Herein, we utilized a comprehensive computational pipeline starting with a network pharmacology analysis to map the pharmacological landscape of the dual-targeted ligands. Thereafter, molecular descriptors were employed to uncover structural similarities between CB2R agonists and M1R-positive allosteric modulators. Promising candidates were further evaluated for their binding affinities to the corresponding receptors by molecular docking studies. Collectively, these integrated computational approaches yielded a shortlist of chemotypes with the potential for dual regulation of CB2R and M1R. These findings provide a computational foundation and potential chemical starting points for future experimental studies aimed at exploring CB2R-M1R dual modulation in intricate neurodegenerative disorders and related conditions.

Identifiers

PMID41799067
PMCPMC12961564

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.